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Abstract 
Objective: The effects of replacing cisplatin (CDDP) with cis-diammineglycolatoplatinum 
(nedaplatin, NDP), a second-generation platinum complex, on the pharmacokinetics of 
5-fluorouracil (5-FU) were investigated in Japanese patients with esophageal squamous cell 
carcinoma, who were treated with a definitive 5-FU/CDDP-based chemoradiotherapy. 
Methods: Fifty-six patients were enrolled, 49 treated with CDDP and 7 treated with NDP. 
A course consisted of continuous infusion of 5-FU at 400 mg/m
2/day for days 1-5 and 8-12, 
infusion of CDDP or NDP at 40 mg/m
2/day on days 1 and 8, and radiation at 2 Gy/day on 
days 1 to 5, 8 to 12, and 15 to 19, with a second course repeated after a 2-week interval. 
Plasma concentrations of 5-FU were determined by high performance liquid chromatogra-
phy at 5 PM on days 3, 10, 38 and45, and at 5 AM on days 4, 11, 39 and 46. 
Results and conclusions: The circadian rhythm in plasma concentrations of 5-FU ob-
served in the case of CDDP was altered when NDP was used instead. The clinical response 
can be predicted by monitoring plasma concentrations of 5-FU in the CDDP group, but not 
in the NDP group. 
Key words: nedaplatin, chemoradiotherapy, esophageal squamous cell carcinoma, 5-fluorouracil, 
plasma concentration 
Introduction 
A clinical report published in 1999, the RTOG 
(Radiation Therapy Oncology Group) 85-01 trial in-
volving 134 patients with T1-3, N0-1 and M0 eso-
phageal cancer, is of great interest in terms of clinical 
outcome because it demonstrated a 5-year survival 
rate of 26 % [1-4]. This treatment consists of infusion 
of 5-fluorouracil (5-FU) and cisplatin (CDDP), and 
concurrent radiation, without pre- or post-surgical 
resection. Simultaneously in Japan, a modified ver-
sion was proposed by Ohtsu and his co-workers for 
advanced metastatic esophageal cancer [5,6]. Two 
independent clinical investigations have shown cura-
tive potential using this regimen for unresectable 
esophageal squamous cell carcinoma (ESCC) with T4 Int. J. Med. Sci. 2009, 6 
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or M1a [5,6]. A long-term evaluation of efficacy and 
toxicity with 139 patients resulted in a complete re-
sponse (CR) rate of 56%, along with a 5-year survival 
rate of 29% [7-9]. Currently, a definitive 
5-FU/CDDP-based chemoradiotherapy (CRT) is rec-
ognized as one of the most promising treatments for 
esophageal cancer [10].  
A series of studies has been performed to find a 
marker predictive of clinical outcome after treatment 
with a definitive 5-FU/CDDP-based CRT [11-13]. A 
total of 8 measurements of the plasma concentration 
of 5-FU were made per patient, and it was concluded 
that the average value was predictive of clinical re-
sponse, but not of severe acute leucopenia, stomatitis 
and cheilitis. Additionally, it has been suggested that 
clinical response and severe acute toxicities may be 
predicted on the basis of genetic polymorphisms. 
CDDP is one of the antitumor agents most 
widely used against several types of solid tumors. 
However, its clinical use is limited by its potent 
nephrotoxicity, which can lead to acute renal failure. 
Nedaplatin (NDP), cis-diammineglycolatoplatinum, is 
a second-generation platinum complex that is ap-
proximately 10 times as soluble in water as CDDP 
[14-16]. As such, NDP is considered to have more 
pronounced activity against solid tumors, but less 
nephrotoxicity and gastrointestinal toxicity than 
CDDP [14]. In phase II clinical studies, NDP was 
found to be highly effective against solid tumors, in-
cluding non-small cell lung cancer, small cell lung 
cancer, head and neck cancer and esophageal cancer 
[15]. The replacement of CDDP with NDP might be of 
value for a certain subpopulation of patients. Al-
though little information is yet available, it was re-
cently reported that NDP was comparable to CDDP 
with regards to clinical response and survival, and 
also to acute and late toxicity in the treatment of 
ESCC [16]. In this study, the effects of replacing 
CDDP with NDP on the pharmacokinetics of 5-FU 
were investigated in ESCC patients treated with a 
definitive 5-FU/CDDP-based CRT. 
Patients and Methods 
Patients 
Fifty-six ESCC patients were enrolled in this 
study based on the following criteria: 1) ESCC treated 
at Kobe University Hospital from August 2002 to 
June 2006; 2) clinical stage T1 to T4, N0 or N1, and M0 
or M1a according to the International Union Against 
Cancer tumor node metastasis (TNM) classification; 
3) age less than 85 years; 4) an Eastern Cooperative 
Oncology Group performance status of 0 to 2; 5) ade-
quate bone marrow, marrow, renal, and hepatic 
function; 6) no prior chemotherapy; 7) no severe 
medical complications; and 8) no other active 
malignancies (except early cancer). The tumors were 
histologically confirmed to be primary, and no pa-
tients with recurrence were included in this study.   
Protocol  
The protocol is presented in Figure 1. A course 
consisted of continuous infusion of 5-FU at 400 
mg/m2/day for days 1-5 and 8-12, infusion of CDDP 
or NDP at 40 mg/m2/day on days 1 and 8, and radia-
tion at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, 
with a second course repeated after a 2-week interval 
[5,6]. If disease progression/recurrence was ob-
served, either salvage surgery, endoscopic treatment, 
or another regimen of chemotherapy was scheduled. 
Forty-nine of 56 patients were treated with CDDP 
(the CDDP group), and the remaining 7 patients were 
treated with NDP (the NDP group). This study was 
conducted with the authorization of the institutional 
review board and followed the medical research 
council guidelines of Kobe University.   
 
 
Figure 1. Protocol of a definitive 
5-fluorouracil (5-FU)/ cisplatin (CDDP) 
or nedaplatin (NDP)-based chemora-
diotherapy. One course of treatment 
consisted of protracted venous infusions 
of 5-FU (400 mg/m
2/day for days 1-5 and 
8-12) and CDDP (or NDP) (40 
mg/m
2/day on days 1 and 8), and radia-
tion (2 Gy/day on days 1-5, 8-12, and 
15-19), with a second course (days 
36-56) was repeated after a 2-week 
interval. Int. J. Med. Sci. 2009, 6 
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Pharmacokinetics of 5-FU 
Aliquots (5 mL) of blood were collected into 
etylenediaminetetraacetic acid-treated tubes at 5 PM 
on days 3, 10, 38 and 45, and at 5 AM on days 4, 11, 39 
and 46 [11-13]. The plasma concentration of 5-FU was 
determined by high-performance liquid chromatog-
raphy as described previously [11-13]. The apparent 
elimination half-life of 5-FU is approximately 10 min-
utes [17], and the plasma concentration will reach a 
steady-state within a few hours of starting continuous 
infusion. The systemic exposure to 5-FU during each 
of 4 cycles was assessed as the area under the con-
centration time curve for 120 hours (AUC120h), calcu-
lated as 120 hours x the average of 2 measurements 
within a cycle.   
 
Clinical Response 
A CR was defined as the complete disappear-
ance of all measurable and assessable disease at the 
first evaluation, which was performed 1 month after 
the completion of CRT to determine whether the dis-
ease had progressed. The clinical response was 
evaluated by endoscopy and chest and abdominal 
computed tomography (CT) scans in each course. A 
CR at the primary site was evaluated by endoscopic 
examination when all of the following criteria were 
satisfied on observation of the entire esophagus: 1) 
disappearance of the tumor lesion; 2) disappearance 
of ulceration (slough); and 3) absence of cancer cells 
in biopsy specimens. If small nodes of 1 cm or less 
were detected on CT scans, the recovery was defined 
as an “uncertain CR” after confirmation of no pro-
gression for at least 3 months. An “uncertain CR” was 
included as a CR when calculating the CR rate. When 
these criteria were not satisfied, a non-CR was as-
signed. The existence of erosion, a granular pro-
truded lesion, an ulcer scar, and 1.2 w/v% io-
dine/glycerin-voiding lesions did not prevent an 
evaluation of CR. The evaluations were performed 
every month for the first 3 months, and when the cri-
teria for CR were not satisfied at 3 months, the result 
was changed to non-CR. Follow-up evaluations were 
performed thereafter every 3 months for 3 years by 
endoscopy and CT scan. After 3 years, patients were 
seen every 6 months. During the follow-up period, a 
routine course of physical examinations and clinical 
laboratory tests was performed to check the patient’s 
health. 
Severe Acute Toxicities  
A definitive 5-FU/CDDP-based CRT is associ-
ated with acute toxicities, predominantly leucopenia, 
stomatitis, and cheilitis [5-9,18]. Toxicity was evalu-
ated using criteria defined by the Japan Clinical On-
cology Group [19]. These criteria were based on the 
National Cancer Institute Common Toxicity Criteria. 
Toxicity was assessed on a 2 to 3 day basis during the 
CRT and subsequent hospitalization period and on 
every visit after the completion of CRT. Episodes of 
leucopenia, stomatitis, and cheilitis during the first 2 
courses and subsequent 2 weeks (until day 70) were 
recorded as acute toxicities and those of grade 3 or 
more as severe acute toxicities. 
Data Analysis and Statistics 
All values reported are the mean±standard de-
viation (SD). The association of disease stage with the 
rates of CR and severe acute toxicities were analyzed 
with Fisher’s exact test. Circadian variations of 
plasma concentrations of 5-FU were analyzed with 
the Wilcoxon signed-rank test. The unpaired Stu-
dent’s t-test/Welch’s test or Mann-Whitney’s U test 
was used for two-group comparisons of the plasma 
concentrations or AUC120h values of 5-FU. P values of 
less than 0.05 (two tailed) were considered to be sig-
nificant.  
Results 
Demographic and clinicopathologic characteris-
tics of 56 ESCC patients are summarized in Table 1. 
The ratio of T1/T2/T3/T4 was 17/6/21/12, that of 
N0/N1 was 23/33, and that of M0/M1a was 45/11, 
resulting in a stage I/II/III/IVa ratio of 13/10/22/11. 
There was no significant difference between the 2 
groups; the CDDP group (N=49) and the NDP group 
(N=7).  
The results of clinical outcome are summarized 
in Table 2. The overall CR rate was 44.6%, and de-
pended on disease stage; 84.6%, 70.0%, 27.3% and 
9.1% for stage I, II, III and IVa, respectively (P<0.05). 
NDP was comparable to CDDP with respect to clini-
cal response, but the treatment with NDP achieved a 
CR at stage IVa (data not shown). Episodes of severe 
acute leucopenia, stomatitis and cheilitis occurred in 
42.9%, 12.5% and 14.3% of cases, respectively, and 
each rate was independent of disease stage (data not 
shown). Replacement of CDDP with NDP had no ef-
fect on the rates of these severe acute toxicities (data 
not shown).   
 Int. J. Med. Sci. 2009, 6 
 
http://www.medsci.org 
308
Table 1. Demographic and Clinicopathologic Characteristics of 56 Japanese Patients with Esophageal Squamous Cell 
Carcinoma 
Characteristics Values 
Age, yr  64.3±7.5 (48 -78) 
Height, cm  163.1±6.7 (150-180) 
Weight, kg  55.9±9.4 (33-79) 
Sex  Male/Female = 51/5 
Race Japanese 
Performance status  0/1/2/unknown = 28/22/4/2   
Histological type  squamous cell carcinoma 
Differentiation well/moderate/poor/unknown  =  8/31/9/8   
T1/T2/T3/T4 = 17/6/21/12 
N0/N1 = 23/33 
TNM score 
 
 
M0/M1a = 45/11 
Stage  I/II/III/IVa = 13/10/22/11 
The values are the mean±SD, with the range in parentheses. TNM score: tumor, node, metastasis. Patients with noncervical primary tumors 
with positive supraclavicular lymph nodes were defined as M1a. 
 
 
Table 2. Clinical Outcome in 56 Japanese Patients with Esophageal Squamous Cell Carcinoma 
  N % 
Clinical Response    
Complete response (CR) rate  25  44.6 
Partial response (PR) rate  24  42.9 
Severe Acute Toxicities      
Leucopenia 24  42.9 
Stomatitis 7  12.5 
Cheilitis 
 
8 
 
14.3 
 
 
 
The plasma concentrations of 5-FU are shown in 
Figure 2. The values of AUC120h are summarized in 
Table 3. In the 1st cycle/1st course, plasma concen-
trations of 5-FU were significantly lower at 5 AM 
(0.076±0.040  μg/mL) than at 5 PM (0.109±0.060 
μg/mL) in the CDDP group (P<0.05, β=0.907). A 
similar tendency was observed in the 2nd cycle/1st 
course (P=0.134, β= 0 . 3 9 0 ) .  I n  t h e  N D P  g r o u p ,  h o w -
ever, concentrations tended to be higher at 5 AM than 
at 5 PM in both the 1st and 2nd cycle/1st course 
(P=0.249,  β=0.106, P=0.463, β=0.138, respectively), 
whereas the AUC120h value of 5-FU in the CDDP 
group was almost the same as that in the NDP group 
in the 1st as well as 2nd cycle/1st course (Table 3). In 
the 1st course, the plasma concentrations of 5-FU at 
both 5 PM and 5 AM were significantly higher in the 
2nd cycle than the 1st cycle in the CDDP group 
(P<0.05,  β=0.951, P<0.05, β=0.999, respectively). 
Similarly in the NDP group, the concentration of 
5-FU tented to increase in the 2nd cycle, but not sig-
nificantly (P=0.116, β=0.205, P=0.173, β=0.211, respec-
tively). These phenomena found in the 1st course 
were also found in the 2nd course, for both groups.   
The correlation between the CR rate and the 
plasma concentration of 5-FU was evaluated, and the 
results obtained with the average value of 8 meas-
urements are summarized in Table 4. In the CDDP 
group, the plasma concentrations of 5-FU were sig-
nificantly higher in the patients with CR than those 
with non-CR (P<0.05), but the inclusion of 7 patients 
treated with NDP resulted in no statistically signifi-
cant difference (P=0.090). The association with severe 
acute toxicities was also evaluated, and the results on 
leucopenia are summarized in Table 5. There was no 
difference in the plasma concentrations of 5-FU be-
tween the patients with and without severe acute 
leucopenia, in either groups. Similarly, the plasma 
concentrations of 5-FU in the patients with severe 
acute stomatitis or cheilitis were comparable to those 
in the patients without (data not shown).   
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Table 3. Area Under the Concentration-Time Curve Values (AUC120h, mg*h/L) of 5-Fluorouracil (5-FU) in 56 Japanese 
Patients with Esophageal Squamous Cell Carcinoma 
CDDP NDP   
  N=49 N=7 
1st cycle / 1st course  11.1±4.8 11.0±4.6    
2nd cycle / 1st course  16.8±6.4 15.3±7.3    
1st cycle / 2nd course  10.7±5.2 10.6±4.4    
2nd cycle / 2nd course 
 
16.0±5.4 
 
15.9±6.8    
 
CDDP: cisplatin, NDP: nedaplatin. Systemic exposure to 5-FU was assessed as the AUC120h, calculated as 120 hours x the average of 2 meas-
urements. There was no significant difference between the 2 groups at each of the 4 cycles.  
 
Table 4. Plasma Concentrations of 5-Fluorouracil (5-FU) in the Patients with and without a Complete Response (CR). 
 
 
CR 
 
non-CR 
 
 
 
 N  5-FU,  μg/mL N  5-FU,  μg/mL P   
 
CDDP 
 
23 
 
0.124±0.035 
 
26 
 
0.105±0.044 
 
0.045 
NDP  2  0.078 , 0.117  5  0.116±0.038  - 
total 
 
25 
 
0.122±0.035 
 
31 
 
0.107±0.043 
 
0.090 
 
CDDP: cisplatin, NDP: nedaplatin. The average of 8 measurements made per patient is listed as the data. In the CDDP group, plasma con-
centrations of 5-FU were significantly higher in the patients with CR than those without (non-CR), but the inclusion of 7 patients treated with 
NDP resulted in no significant differences. 
 
Table 5. Plasma Concentrations of 5-Fluorouracil (5-FU) in the Patients with and without Severe Acute Leucopenia. 
  Severe Acute Leucopenia  No Severe Acute Leucopenia   
 
 
N 
 
5-FU, μg/mL 
 
N 
 
5-FU, μg/mL 
 
P 
 
CDDP 21  0.116±0.036  28  0.113±0.033  0.785 
NDP 3  0.114±0.053  4  0.109±0.021  0.869 
total 24  0.115±0.037  32 
 
0.112±0.031 0.746 
CDDP: cisplatin, NDP: nedaplatin. The average of 8 measurements made per patient is listed as the data. There was no difference between 
the patients with and without severe acute leucopenia, in either group. 
 
 
Figure 2. Plasma concentrations 
of 5-fluorouracil (5-FU) in 56 pa-
tients with esophageal cancer. A 
total of 8 measurements were 
made per patient: 5 PM on days 3, 
10, 38 and45, and 5 AM on days 4, 
11, 39 and 46. Closed circle: the 
cisplatin (CDDP) group (N=49), 
open circle: the nedaplatin (NDP) 
group (N=7). The bars represent 
the SD. * P<0.05; significant dif-
ferences were observed in the 
CDDP group, but not in the NDP 
group. 
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Discussion 
Esophageal cancer is the 8th most common can-
cer in the world and one of the most lethal [10]. 
Symptoms include dysphagia, odynophagia, and 
progressive weight loss. The two predominant histo-
logical subtypes are adenocarcinoma and squamous 
cell carcinoma, and treatment depends on the loca-
tion of the primary tumor, the disease stage, patient 
characteristics and co-morbidities, and occasionally, 
histological subtype. There is no consensus on an op-
timal treatment strategy for esophageal cancer, and 
treatments include surgical procedures, radiation, 
chemotherapy, and combinations thereof [10]. In pa-
tients with localized squamous cell carcinoma, a de-
finitive 5-FU/CDDP-based CRT is one of the most 
promising ways to achieve a complete pathologic re-
sponse. The treatment might be improved further 
through modification of the treatment schedule, dose 
escalation and the replacement of 5-FU and CDDP. 
Capecitabine or tegafur/uracil might provide better 
results than 5-FU, and oxaliplatin and NDP are po-
tential substitutes for CDDP. 
In this study, we investigated the effects of re-
placing CDDP with NDP in 56 ESCC patients treated 
with a definitive 5-FU/CDDP-based CRT, and found 
no significant differences in clinical outcome, i.e., the 
CR rate and the severe acute toxicities, in the NDP 
group, when compared with the CDDP group. Al-
though multi-center, cross-over style clinical investi-
gations should be conducted on the replacement, 
NDP may be beneficial to ESCC patients, especially 
those with renal disease. Yamashita et al. [16] also 
reported that NDP did not differ from CDDP with 
regards to overall survival, progression-free survival 
and severe acute leucopenia in the treatment of lo-
cally advanced and metastatic esophageal cancer.   
Herein, it was clarified that NDP has substantial 
effects on the pharmacokinetics of 5-FU. It is 
well-known that there is a circadian rhythm in drug 
metabolism, cellular proliferation and physiological 
function, and the suprachiasmatic nuclei, a hypotha-
lamic pacemaker clock, is important for the rhythm 
[20-22]. As a result, both the toxicity and efficacy of 
over 30 anticancer agents vary as a function of dosing 
time [20-22]. More than 80 % of the administered 
5-FU is eliminated by the rate-limiting enzyme, dihy-
dropyrimidine dehydrogenase (DPD). The DPD ac-
tivity is found in most tissues, but is highest in the 
liver. The activity of DPD of diurnally active cancer 
patients varies significantly during a 24-hour time 
period, and is greatest from midnight to early morn-
ing [21-24], being consistent with the findings of this 
study. However, in the NDP group, the pattern of 
circadian rhythm in 5-FU pharmacokinetics was cer-
tainly different from that in the CDDP group, al-
though the AUC120h values were not altered (Table 3). 
The interaction of DPD with CDDP might be different 
from that of NDP, but there is no rational explanation 
for these phenomena. Further clinical and 
non-clinical investigations should be conducted.   
The plasma concentrations of 5-FU were predic-
tive of clinical response, but not of severe acute tox-
icities, in the CDDP group (Tables 4, 5), however the 
inclusion of 7 patients treated with NDP affected 
predictions, presumably because clinical response 
cannot be predicted on the basis of plasma concentra-
tions of 5-FU in the NDP group. A number of clinical 
investigations on colorectal cancer and head and neck 
cancer have revealed that the plasma concentrations 
of 5-FU were associated with treatment efficacy and 
toxicity, and the target level of 5-FU concentrations to 
ensure a certain efficacy was presented [25]. The tar-
get level might be proposed also for ESCC, but when 
using NDP instead of CDDP, it is necessary to look 
for some marker capable of indicating clinical re-
sponse.  
In conclusion, only a small number of patients 
were enrolled in this study, especially in the NDP 
group, and we had no conclusions on the replace-
ment of CDDP with NDP in terms of clinical outcome 
after the definitive 5-FU/CDDP-based CRT. The cir-
cadian rhythm in plasma concentrations of 5-FU ob-
served with CDDP was altered when NDP was used 
instead, and clinical response can be predicted on the 
basis of the plasma concentrations of 5-FU in the 
CDDP group, but not in the NDP group. 
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